← All trials
NCT02799368
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 1, 2016
- Primary completion
- Nov 1, 2018
- Completion date
- May 1, 2020
- First posted
- —
- Last posted
- —
- Enrollment
- 1660
- Arms / groups
- 2 / —
- Source
- AACT · pre-existing
Sponsors
- Seoul National UniversityLead sponsor
- Cha Medical UniversityCollaborator
- Seoul National UniversityStudy chair
- Yonsei UniversityCollaborator
- Gachon UniversityCollaborator
- Seoul National UniversityCollaborator
- Seoul National UniversityReponsible party - principal investigator
- Ilsan HospitalCollaborator
- Catholic University of KoreaCollaborator
- Kyungpook UniversityCollaborator
- Ewha Womans UniversityCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.